SightfileU.S. market data from official filings

ENANTA PHARMACEUTICALS INC (ENTA)

Name: ENANTA PHARMACEUTICALS INC (ENTA) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001177648 · EDGAR filings · Updated 2026-07-02

ENANTA PHARMACEUTICALS INC (ENTA) has reported institutional ownership of 92.1%, with 132 institutional managers holding positions valued at $338.1M per the latest 13F reporting period.

Institutional ownership

92.1%

Institutional managers

132

Reported 13F value

$338.1M

Insider activity

36 trans.

−$183.2K net selling

Latest updates

2026-07-02 — Current report (8-K) filed
2026-07-02 — Prospectus supplement (424B5) filed
2026-06-23 — Current report (8-K) filed
2026-06-18 — Current report (8-K) filed
2026-05-13 — Employee-plan registration (S-8) filed
2026-05-13 — Quarterly report (10-Q) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ENANTA PHARMACEUTICALS INC has 132 institutional holders and institutional ownership of 92.1%.

Insider activity

Insiders reported 36 transactions (0 buys, 9 sells) across 8 reporting insiders, with a net reported value of −$183.2K.

Related companies

MONOPAR THERAPEUTICS INC (MNPR) · AURA BIOSCIENCES INC (AURA) · TENAX THERAPEUTICS INC (TENX) · PERSPECTIVE THERAPEUTICS INC (CATX) · OMEROS (OMER) · ATEA PHARMACEUTICALS INC (AVIR)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.